Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the Acute Leukemia Working Party (ALWP) registry of the European Society for Blood and Marrow Transplantation (EBMT). We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty-seven (38.0%) patients underwent myeloablative conditioning and 97 (62.0%) reduced intensity conditioning (RIC) conditioning. Multivariate analysis showed that there was no difference in RI, nonrelapse mortality (NRM), leukemia free survival (LFS), overall survival (OS), or GVHD-free/ relapse free survival (GRFS) for conditioning intensity, age, performance status, or graft source.
donor remains the preferred option for transplantation, there is a substantial lack of this donor population for sAML patients with rates estimated to be as high as 70%. [3] [4] [5] Haploidentical HCT (haploHCT) is gaining traction within the field of transplantation as a viable donor source when an HLA matched donor is not available. 4, 6, 7 HaploHCT was previously limited by significant non engraftment and graft versus host disease (GVHD) but in recent years with improvements in conditioning regimens and new strategies to prevent GVHD and facilitate immune reconstitution have led to more favorable outcomes comparable to those of HLA-matched allogeneic HCT. [7] [8] [9] [10] Currently published studies for haploHCT are mostly in de novo AML and there are currently no large scale studies for haploHCT in sAML.
| M E TH ODS

| Study population
This was a retrospective registry study performed at and approved by GVHD-free/relapse free survival (GRFS), and overall survival (OS)). Regimens were classified as myeloablative conditioning (MAC) or reduced intensity conditioning (RIC) based on published criteria. 11 Grading of acute and chronic GVHD was performed using established criteria.
12,13
| Statistical analysis
The outcomes evaluated included (i) NRM, defined as death without relapse, (ii) relapse incidence, defined on morphological evidence of leukemia in the bone marrow or extramedullary organs, (iii) leukemia-free survival, defined as time from transplantation to relapse or death after complete remission, (iv) overall survival, and (v) GRFS, defined as time from transplantation to events including grade III-IV acute GVHD, extensive chronic GVHD, relapse, or death from any cause after haploHCT. 14 
| Graft-versus-host disease
The cumulative incidences of acute GVHD grade II-IV and severe acute GVHD (III-IV) were 26.6% and 9.8% at day 100, respectively.
For the patients in CR, acute GVHD (III-IV) was 6.1% (95% CI 1. were no statistically significant differences in the incidence of acute GVHD based on any of the other patient, disease, or transplant characteristics.
The cumulative incidences of chronic GVHD and extensive chronic GVHD were respectively 26.0% and 9.0% two years after transplantation. Univariate and multivariate analyzes did not show any significant differences in patient, disease, or transplant characteristics.
| T-cell depletion with ATG versus PTCy
T-cell depletion with ATG has been commonly used for prevention of acute and chronic GVHD with previous data indicating mixed results in terms of outcomes. [15] [16] [17] [18] Patients who received ATG had inferior GRFS compared to those who did not (HR 1.73, 95% CI 1.13-2.63, P 5 .01).
| D ISC USSION
Secondary AML encompasses a heterogeneous group who have been previously heavily pretreated with inferior outcomes compared with de novo AML. Currently, the only potential cure for sAML is allogeneic HCT but not every patient in need of transplantation has an HLAmatched sibling or unrelated suitable donor. HaploHCT has the potential to fill a substantial therapeutic gap for these patients without a matched related or unrelated donor. Several retrospective studies have compared haploHCT to HLA-matched allogeneic HCT for de novo AML but not in sAML. 4, 19 Initial experiences with haploHCT in the 1990s resulted in poor outcomes due to T-cell alloreactivity secondary to HLA-mismatches with delayed engraftment, graft failures, and relatively high incidences of acute GVHD. 4, 19, 20 Several strategies were developed to overcome these challenges, including ex vivo and in vivo TCD as well as T-cell replete (TCR) grafts. 4, 16 In vivo TCD with ATG has become a commonly used practice for GVHD prophylaxis in haploHCT, especially in China, with improvement in achieving primary engraftment, reducing RI, and minimizing GVHD. 17, 19, 21, 22 However, in vivo TCD is known to be associated with a high incidence of infection and NRM leading to increased morbidity and mortality. 23 PTCy was initially introduced by O'Donnell et al. 24 followed by a prospective trial by Luznik et al. 25 that
showed low incidences of GVHD, results which were subsequently confirmed by other studies. 26, 27 PTCy has been shown in murine models to target recipient and donor activated alloreactive T-cells reducing the risk of rejection and GVHD when given in a short window after allografting. 28 Additionally, multiple studies have shown that haploHCT with PTCy had relatively low rates of NRM and improved OS. The initial drawback of PTCy was reported to be a high incidence of RI with rates up to 51%. 25 Notably, the RI in our study with PTCy was receiving BM (n 5 481) and PB (n 5 190) haploHCT with lower rates of acute GVHD grade II-IV and chronic GVHD with BM compared with PB. There was increased RI with BM but specifically in the patients with leukemia population which are similar to the results obtained in our study. 37 Disease status did make a major difference for multiple outcome measures including RI, LFS, OS, and GRFS. This is consistent with previous publications in patients with AML and other hematologic malignancies undergoing haploHCT in which active disease was associated with significantly poor outcomes including relapse rates greater than 50% and increased NRM leading to OS less than 20%. 25, 29, 32, [39] [40] [41] While the trend of ATG in active disease does show higher NRM with lower LFS, OS, and GRFS, no clear conclusions can be drawn as the number of patients who received ATG was too low for statistical power.
Being a registry based our study is with several limitations including heterogeneity in conditioning and GVHD prophylaxis regimens and some missing data including comorbidity scores other than Karnofsky scores. In addition, it is conceivable that additional modifying factors
were not analyzed as this is an inherent limitation of retrospective studies. However, in the absence of prospective data, our study of haploHCT in a rather large cohort of sAML is of clinical importance. 
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